K Kario Selected Research

Therapeutics

11/2014	Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension.
8/2010	Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

K Kario Research Topics

Disease

7	Hypertension (High Blood Pressure) 04/2022 - 05/2000
6	Stroke (Strokes) 08/2010 - 03/2001
4	Cerebral Infarction 08/2001 - 01/2000
3	Coronary Artery Disease (Coronary Atherosclerosis) 07/2001 - 01/2000
2	White Coat Hypertension 01/2016 - 12/2013
2	Protein C Deficiency 08/2001 - 01/2000
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 08/2001 - 01/2000
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2001 - 01/2000
2	Myocardial Infarction 01/2000 - 01/2000
1	Pre-Eclampsia (Preeclampsia) 01/2016
1	Pregnancy-Induced Hypertension (Hypertension, Pregnancy Induced) 01/2016
1	Pulmonary Hypertension 11/2014
1	Essential Hypertension 12/2013
1	Isolated Systolic Hypertension 10/2001
1	Spasm (Spasms) 07/2001
1	Coronary Stenosis (Coronary Artery Stenosis) 07/2001
1	Hyperinsulinism (Hyperinsulinemia) 03/2001
1	Arteriovenous Fistula 09/2000
1	Coronary Disease (Coronary Heart Disease) 09/2000
1	Disseminated Intravascular Coagulation 01/2000
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2000
1	Lacunar Stroke 01/2000

Drug/Important Bio-Agent (IBA)

5	Antihypertensive Agents (Antihypertensives)IBA 04/2022 - 01/2000
2	4- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA 03/2014 - 12/2010
2	Protein CIBA 08/2001 - 01/2000
1	SolutionsIBA 04/2022
1	N 30IBA 01/2016
1	Bosentan (Tracleer)FDA Link 11/2014
1	olmesartanIBA 12/2013
1	Angiotensin Receptor AntagonistsIBA 12/2013
1	Tissue Plasminogen Activator (Alteplase)FDA Link 08/2010
1	Protons (Proton)IBA 08/2001
1	Blood Proteins (Serum Proteins)IBA 08/2001
1	Acetylcholine (Acetylcholine Chloride)FDA Link 07/2001
1	Indicators and Reagents (Reagents)IBA 06/2001
1	Natriuretic AgentsIBA 04/2001
1	Peptides (Polypeptides)IBA 04/2001
1	Vasodilator Agents (Vasodilators)IBA 04/2001
1	AdrenomedullinIBA 04/2001
1	Hemostatics (Antihemorrhagics)IBA 03/2001
1	Heparin (Liquaemin)FDA LinkGeneric 09/2000
1	von Willebrand FactorIBA 05/2000
1	Factor VII (Proconvertin)IBA 01/2000
1	Factor VIIa (Activated Factor VII)IBA 01/2000
1	EnzymesIBA 01/2000
1	FibrinIBA 01/2000
1	ImmunosorbentsIBA 01/2000
1	LatexIBA 01/2000
1	CalciumIBA 01/2000
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2000
1	fibrin fragment D (D-dimer)IBA 01/2000

Therapy/Procedure

2	Therapeutics 11/2014 - 08/2010
1	Endarterectomy (Thromboendarterectomy) 11/2014